Shots:

• Amgen to acquire all of the outstanding shares of Five Prime for $38.00 /share in cash- representing an equity value of ~ $1.9B. The transaction is expected to close in Q2’21
• The acquisition will add Five Prime's innovative pipeline to Amgen thus expanding its oncology portfolio and supports its international expansion strategy
• Five Prime’s bemarituzumab complements Amgen’s oncology portfolio. Bemarituzumab- is a first-in-class- P-III ready anti-FGFR2b Ab that demonstrated improvement in PFS- ORR- OS in the frontline treatment of patients with advanced gastric or GEJ cancer in its P-II study

 ­ Ref: PRnewswire | Image: PRNewswire